II. History
- Willow bark contains Salicin (Salicylic acid)- Used in folk medicine for mild pain and fever
 
- Acetylsalicylic Acid is a derivative of salicylic acid- Synthesized in 1853 by the Bayer brothers
 
III. Indications
- Analgesia in rheumatic conditions- Other agents including NSAIDs are preferred for analgesia
 
- Prevention of coronary and cerebrovascular events- See Cardiac Risk Management
- Mainstay of secondary and tertiary cardiovascular prevention
- Has fallen out of favor for primary cardiovascular disease prevention aside from high risk patients age 40 to 60 years- See decision aid in resources below
 
 
- 
                          Preeclampsia Prevention
                          - Pregnant women at moderate to high risk of Preeclampsia
- Typically started at 12-16 weeks gestation
 
- 
                          Colorectal Cancer survivors- May reduce recurrence in specific gene mutations
 
IV. Contraindications
- Children with viral illness (Varicella, Influenza)- Risk of Reye's Syndrome (FDA Black Box Warning)
 
- Gout
- Hypersensitivity to Aspirin
- Active Peptic Ulcer Disease
V. Mechanism
- Aspirin irreversibly inactivates cyclooxygenase (COX)- Blocks Thromboxane and Prostaglandin synthesis
- Contrast with NSAIDS which reversibly block COX
 
- 
                          Platelet Effects (Thromboxane-related)- Inhibits Platelet aggregation via cyclooxygenase blockade of Thromboxane A2 synthesis
- Aspirin Irreversibly poisons Platelets for their remaining life (8-10 days)
- New Platelets are generated at a rate of 10% per day (25,000/day for a patient with a 250,000 Platelet Count)- By 2 days off Aspirin, a patient will have 50,000 normal Platelets (enough to counter bleeding)
- By 7 days off Aspirin, a patient will have 70% or 175,000 normal Platelets (typical level required for elective surgery)
- By 10 days off Aspirin, a patient will have 100%normal Platelets (level required by some clinicians for major surgery)
 
 
- 
                          NSAID effects (Prostaglandin-related)- Antipyretic (Lowers Temperature)
- Antiinflammatory effect- Inhibits Prostaglandin biosynthesis at higher dose
 
- Analgesic effect- Relieves pain of mild to moderate intensity at low dose
 
 
VI. Medications: Regular Release Aspirin
- Strengths- Low dose (baby ASA): 81 mg (range 75 to 100 mg)
- Higher dose: 325 mg (range 200 to 325 mg)
 
- Formulations- Immediate release tablets
- Enteric coated
- Buffered
 
- Combinations (examples)- Aspirin with Dipyridamole (Aggrenox)
- Aspirin with Acetaminophen and Caffeine (Excedrin Migraine)
 
VII. Medications: Extended Release Aspirin
- Durlaza (	Extended-release Aspirin)- No evidence that extended release Aspirin ($6/pill) has advantages over Aspirin 81 mg ($0.01/pill)
- (2015) Presc Lett 22(12): 71
 
- Vazalore (liquid-filled Aspirin capsule)- Designed for delayed absorption to Small Intestine, postulated to reduce Gastrointestinal Bleeding
- No evidence that Vazalore reduces longterm Gastrointestinal Bleeding risk
- Expensive ($1 per capsule, compaired with $0.01/pill of standard Aspirin)
- (2021) Presc Lett 28(11): 62
 
VIII. Dosing
- Use lowest appropriate dose (reduces adverse effects)
- Anti-Platelet action- General- Do not exceed 81 to 160 mg daily if on Coumadin
 
- Coronary Artery Disease- See Cardiovascular Disease-related Antiplatelet Use
- Immediate Myocardial Infarction Management: 325 mg
- Primary coronary disease prevention: 81 mg orally daily- As of 2018, Aspirin is no longer recommended for primary prevention in most patients
 
- Tertiary prevention (post-MI)- Aspirin  81 mg orally daily- Similar efficacy in coronary disease prevention as the 325 mg dose
- Half the risk of gastrointestinal Hemorrhage as the 325 mg dose
 
- References
 
- Aspirin  81 mg orally daily
 
- Cerebrovascular Accident- See Antiplatelet Therapy in CVA and TIA
- Prevention in known vascular disease: 81 to 325 mg orally daily
- OConnor (2001) Am J Cardiol 88:541-6 [PubMed]
 
 
- General
- Antipyretic or Analgesic Dose- Adult: 600 mg PO q4 hours
- Adult: 650-1000 mg PO q4-6 hours
 
- Antiinflammatory dose- Adult: 4 grams maximum per day
 
IX. Management: Reversal
- Platelet Transfusion 1 unit (6 pack)
- Consider Desmopressin (DDAVP) 0.3 mcg/kg (expert opinion)
- Consider Recombinant activated Clotting Factor VII (rFVIIa) 30-90 mcg/kg (expert opinion)
X. Pharmacokinetics
- Aspirin is rapidly absorbed in the upper Small Intestine
- Hepatic metabolism
XI. Drug Interactions
- Ibuprofen inactivates Aspirin Anticoagulation effect
XII. Adverse Effects
- Gastrointestinal Effects- Gastrointestinal intolerance
- Peptic Ulcer Disease (Erosive Gastritis)- Aspirin higher risk for Peptic Ulcer Disease
- Other Salicylates have lower risk than most NSAIDs
 
- Gastrointestinal Bleeding- Middle aged: 2-4 per 1000 on Aspirin 5 years
- Older patient: 4-12 per 1000 on Aspirin for 5 years
- Roderick (1993) Br J Clin Pharmacol 35:219-26 [PubMed]
 
 
- Central Nervous System Effects: Salicylism
- Central Respiratory effects- Very high dose: Hyperpnea
- Lethal doses: Respiratory depression or apnea
 
- Miscellaneous Effects- Serum Uric Acid changes
- Asymptomatic hepatitis
- Exacerbation of Renal Insufficiency
- Hypersensitivity Reaction (Aspirin Allergy)- Associated with Nasal Polyps and Asthma
 
 
XIII. Safety
- Pregnancy Category D in third trimester (Category C in first and second trimesters)
- 
                          Lactation
                          - Low dose Aspirin (75 to 325 mg/day) results in minimal to no Aspirin in Breastmilk
- High dose Aspirin is excreted in Breast Milk and is not recommended (risks include Reye's Syndrome)
- LactMed Database
 
XIV. Efficacy
- Safer and lower cost than many NSAIDs- Aspirin is an underused medication
 
- Coronary disease prevention- Falling out of favor in the primary prevention of lower risk patients without Myocardial Infarction or stroke- Number Needed to Treat: 1 in 250 to prevent one first cardiovascular event (primary prevention)
- Aspirin is still an important mainstay of secondary prevention (known cardiovascular disease)
- Aspirin is still considered beneficial for primary prevention when 10 year CVD risk >10% in age 40 to 60 years
- Aspirin risk may outweigh benefit over age 75 years (consider discontinuing Aspirin in advanced age)
 
- Benefits may not outweigh the risks of GI Bleeding, Hemorrhagic CVA- Number Needed to Harm: 1 in 200 to result in major bleeding
- Hemorrhage risk increases with older age, male gender, Tobacco Abuse, NSAID and Anticoagulant use
 
- References
 
- Falling out of favor in the primary prevention of lower risk patients without Myocardial Infarction or stroke
- Other benefits- May reduce Colorectal Cancer risk (NNT 77)
 
XV. Resources
- Aspirin (DailyMed)
- Aspirin Guide- http://www.aspiringuide.com/
- Web-based Shared Decision Making tool for primary prevention use
 
XVI. References
- McCarty (1972) Arthritis and Allied Conditions
- Katzung (1989) Basic and Clinical Pharmacology
- (2000) Med Lett Drugs Ther 42(1085):73-8 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| aspirin (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| ASPIRIN 325 MG TABLET | Generic OTC | $0.01 each | 
| ASPIRIN 81 MG CHEWABLE TABLET | Generic OTC | $0.03 each | 
| ASPIRIN EC 325 MG TABLET | Generic OTC | $0.02 each | 
| ASPIRIN EC 81 MG TABLET | Generic OTC | $0.02 each | 
| ASPIRIN REGIMEN 81 MG EC TAB | Generic OTC | $0.02 each | 
| ASPIRIN-DIPYRIDAM ER 25-200 MG | Generic | $0.76 each | 
| asa (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| ASA-BUTALB-CAFF-COD #3 CAPSULE | Generic | $1.23 each | 
